The Clorox Company (NYSE:CLX) Position Lessened by Kintegral Advisory LLC

Kintegral Advisory LLC trimmed its position in shares of The Clorox Company (NYSE:CLX - Free Report) by 32.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,140 shares of the company's stock after selling 4,974 shares during the period. Kintegral Advisory LLC's holdings in Clorox were worth $1,493,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Redwood Park Advisors LLC acquired a new stake in Clorox during the fourth quarter worth about $26,000. Millstone Evans Group LLC bought a new position in Clorox during the fourth quarter worth about $31,000. Wood Tarver Financial Group LLC bought a new position in Clorox during the fourth quarter worth about $31,000. GKV Capital Management Co. Inc. bought a new position in Clorox during the fourth quarter worth about $32,000. Finally, Aster Capital Management DIFC Ltd bought a new position in Clorox during the fourth quarter worth about $33,000. 78.53% of the stock is currently owned by hedge funds and other institutional investors.

Clorox Stock Performance

CLX stock opened at $124.80 on Friday. The company has a debt-to-equity ratio of 13.07, a current ratio of 0.74 and a quick ratio of 0.44. The company has a 50 day moving average price of $129.65 and a 200 day moving average price of $143.86. The Clorox Company has a fifty-two week low of $117.35 and a fifty-two week high of $171.37. The stock has a market capitalization of $15.38 billion, a PE ratio of 22.41, a price-to-earnings-growth ratio of 3.04 and a beta of 0.51.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 324.23% and a net margin of 9.89%. The company had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. During the same quarter last year, the firm earned $1.71 EPS. The business's revenue for the quarter was down 8.0% on a year-over-year basis. Analysts forecast that The Clorox Company will post 7.15 EPS for the current year.

Insider Buying and Selling

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the stock in a transaction on Wednesday, May 7th. The stock was purchased at an average price of $136.57 per share, with a total value of $546,280.00. Following the acquisition, the director owned 4,000 shares of the company's stock, valued at approximately $546,280. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.57% of the company's stock.

Wall Street Analysts Forecast Growth

CLX has been the subject of a number of analyst reports. Jefferies Financial Group cut their price target on shares of Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Morgan Stanley cut their price target on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. JPMorgan Chase & Co. cut their price target on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. Barclays cut their target price on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a research note on Wednesday, May 7th. Finally, Wells Fargo & Company cut their target price on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $149.50.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.